New Real-World study tests triple inhaler for COPD relief

NCT ID NCT06511193

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 152 COPD patients who started using a triple-combination inhaler (BGF) as part of their routine care. Researchers measured changes in symptoms and quality of life after 12 and 24 weeks. The goal was to see if the inhaler helps patients feel better and have fewer exacerbations in everyday life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Budesonide/Glycopyrronium/Formoterol (BGF) triple-combination inhaler
What this could lead to: If successful, this study could show that BGF helps COPD patients breathe easier and have fewer flare-ups in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also completed, so findings are limited to the 152 participants and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Research Site

Windsor, Ontario, N8W 5V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.